Kyverna Therapeutics Unveils Compelling Data on Autoimmune CAR T Therapy: Potential Game-Changer for SPS and gMG

Introduction

Kyverna Therapeutics, Inc. has released a comprehensive update highlighting transformative clinical data from its neuroimmunology franchise presented at the American Academy of Neurology (AAN) meeting. The focus is on its lead candidate, mivocabtagene autoleucel (miv-cel), a fully human autologous CD19 CAR T-cell therapy, targeting severe autoimmune diseases including Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG). This update includes primary analysis from the SPS registrational trial and longer-term follow-up from the gMG Phase 2 study, positioning miv-cel as a potential first-in-class and best-in-class therapy for these high unmet need indications.

Key Points and Potential Price-Sensitive Highlights

Solidifying Leadership in Autoimmune CAR T

• Lead Indications: SPS and gMG, diseases with significant unmet medical needs.
• Transformative Results: Miv-cel demonstrates drug-free, disease-free remission with a single dose.
• BLA Submission Underway: Preparations for Biologics License Application (BLA) for SPS, indicating near-term commercialization potential.
• Phase 3 gMG Trial: Enrollment has begun, with 14 sites activated globally, paving the way for a significant market opportunity.

Clinical Data Highlights: SPS (KYSA-8 Registrational Trial)

• No FDA-Approved Therapies for SPS: SPS is a debilitating, progressive autoimmune disease with devastating impact; 80% of patients lose mobility, and only 19% retain ability to work after 4 years.
• Study Design: Open-label, single-arm, multicenter trial with 26 patients. Primary endpoint was improvement in the Timed 25-Foot Walk (T25FW) at 16 weeks.
• Primary Endpoint Met:
  • 46% median improvement in T25FW at Week 16.
  • 81% achieved clinically meaningful improvement (≥20% reduction from baseline).
  • 31% completed T25FW in less than 5 seconds, typical for healthy adults.
  • 67% of those needing walking aids at baseline no longer required assistance at Week 16.
  • 100% free of immunomodulatory or immunosuppressant therapies for SPS at last follow-up.
• Secondary Endpoints:
  • Significant improvements in disability, mobility, stiffness, and hypersensitivity (P < .0001).
  • 96% of patients improved in ≥1 primary or secondary efficacy endpoint.
• Additional Efficacy:
  • Substantial improvements in physical and mental functioning (SF-36 scores comparable to healthy adults).
  • Median 89-meter improvement in 6-minute walk test.
• Mechanistic Insights:
  • Robust CAR T-cell expansion led to complete B-cell depletion and significant reductions in autoantibody titers (GAD65-IgG).
  • Evidence of broad immune reset, with increased naïve B-cell phenotype and regulatory T cells at Week 16.
• Safety:
  • No high-grade CRS or ICANS observed.
  • Adverse events were manageable; most common included mild CRS (92%), fatigue (54%), diarrhea (38%), and headache (31%).
  • Grade 3/4 neutropenia occurred in 4 patients but was expected and resolved, with no serious infections.
  • Treatment-related serious adverse events in 3 patients, all resolved without sequelae.
• Potential for Drug-Free, Durable Remission: Single dose resulted in robust, rapid, sustained improvements with consistent safety profile and outpatient potential.

Clinical Data Highlights: gMG (KYSA-6 Phase 2/3 Trial)

• High Disease Burden: Despite available treatments, few gMG patients achieve minimal symptom expression, and most require chronic immunosuppressants.
• Phase 2 Study Design: Open-label, single-arm multicenter study with 7 patients. Primary endpoint: MG-ADL at 24 weeks.
• Results:
  • Rapid, robust reductions in MG-ADL (mean -8.5 at Week 24) and QMG (mean -11.3 at Week 24), sustained to 52 weeks.
  • 100% of patients achieved clinically meaningful response (≥3-point MG-ADL reduction).
  • 57% reached minimal symptom expression (MG-ADL score of 0-1) at last follow-up.
  • 100% were free of immunotherapies, including NSISTs, high-dose steroids, FcRn, and complement inhibitors up to 24 weeks; 6 of 7 remained free at last follow-up.
  • Miv-cel reduced autoantibody levels (AChR and MuSK) while preserving humoral immunity.
• Safety:
  • No high-grade CRS or ICANS observed.
  • CRS was low-grade and manageable; neutropenia occurred but was expected and resolved.
  • No serious adverse events after investigator review.
• Immune Reset: Evidence of deep B-cell depletion and immune reset, with preserved humoral immunity.

Comparative Outcomes and Market Opportunity

• Unprecedented Clinical Outcomes: Miv-cel demonstrated superior MG-ADL and QMG reductions, responder rates, and minimal symptom expression compared to FcRn inhibitors, complement inhibitors, CD19/BCMA mAb, and investigational mRNA CAR T therapies.
• Focused Launch Strategy for SPS:
  • Miv-cel could be the first and only approved therapy for SPS, with approximately 6,000 diagnosed patients in the U.S., including 2,000-2,500 prioritized for miv-cel based on current treatment patterns.
  • Survey of SPS treaters shows strong enthusiasm for early adoption; 80% view efficacy data as compelling, 90% see one-time treatment as a key attribute, and 85% would use miv-cel for moderate-to-severe patients at launch.
  • Launch strategy targets ~10 high-value SPS centers with robust CAR T expertise and commercial payer support.
• Financial and Commercial Outlook:
  • Kyverna is positioned for BLA submission and anticipated commercial launch in SPS, with expansion to gMG and other indications supported by ongoing Phase 3 trials.
  • Potential for premium pricing and strong financial position as Kyverna delivers the curative potential of CAR T in autoimmune diseases.

Potential Share Price Impact

Key drivers for share price movement include:

• Successful completion of registrational SPS trial with robust efficacy and safety data.
• Initiation of BLA submission process for SPS, signaling potential near-term commercial approval.
• Rapid progress in gMG Phase 3 trial, with globally activated sites and strong efficacy signals.
• First-in-class and best-in-class positioning of miv-cel for autoimmunity, with potential to disrupt current chronic treatment paradigms.
• Strong physician and market enthusiasm for early adoption, supporting commercial uptake.
• Focused launch strategy and premium pricing potential in rare disease markets.

Conclusion

Kyverna Therapeutics’ latest data on miv-cel marks a significant milestone in the development of curative therapies for autoimmune diseases. The clinical evidence supports durable, drug-free remissions in SPS and gMG, with a manageable safety profile and robust commercial prospects. With BLA submission preparations underway and Phase 3 trials advancing, Kyverna is poised for potential value inflection and leadership in neuroimmunology.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties. Actual results may differ materially from those anticipated. Investors are advised to review all regulatory filings and consult with financial advisors before making investment decisions. Kyverna Therapeutics, Inc. undertakes no obligation to update or revise statements herein.

View Kyverna Therapeutics, Inc. Historical chart here